Evidence map›Paper›PMID 40512290›Full record

ArticleNeurochemical research2025

Hydroxysafflor Yellow A Ameliorates Ischemic Stroke by Inhibiting NLRP3, AIM2, and Pyrin Inflammasome-Mediated Pyroptosis.

Ye-Ling Ding, Li-Jun Qiao, Hao Fang, Ling-Ling Fan, Dan Wu, Jian-Peng Xu, Qi-Hong Lv, Min-Zhen Deng, Yu-Hui Qiu, Zi-Yi Zhou and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Discovery of (Molecules (Basel, Switzerland) · 2025
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ye-Ling Ding *State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Li-Jun Qiao *State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Hao FangState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Ling-Ling FanState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Dan WuState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Jian-Peng XuState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Qi-Hong LvState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Min-Zhen DengState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Yu-Hui QiuState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Zi-Yi ZhouState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Yan HuangState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China.
Jia-Yi ZhengState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China. zhengjiayi@gzucm.edu.cn.
Shi-Jie ZhangState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China. shijiezhang@gzucm.edu.cn.
Ye-Feng CaiState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, 510405, China. caiyefeng@126.com.

Funding

Administration of Traditional Chinese Medicine of Guangdong Province 20231117Guangdong Provincial Key Laboratory of Research on Emergency in TCM 2023B1212060062
6 · The paper itself

Abstract

Hydroxysafflor Yellow A (HSYA), a water-soluble compound derived from the traditional Chinese medicine Carthamus tinctorius L., is known for its protective effects against cerebral ischemia/reperfusion(I/R) injury, though its mechanism remains unclear. This study investigated the effect of HSYA on cerebral I/R injury and its potential relation to pyroptosis. Adult male Sprague-Dawley rats were divided into sham-operated, model, and HSYA-treated groups. HSYA was administered as a pretreatment for 5 days before constructing the cerebral I/R injury model. Neurological function scores, TTC staining, HE staining, Nissl staining, immunofluorescence staining, SOD, GSH, GSH-Px, MDA, LDH Assays, PCR, western blotting, and ELISA were used to assess HSYA's effects. HSYA pretreatment improved neurological deficits and pathological state of brain tissue and reduced infarct area. It raised SOD, GSH, and GSH-Px activities, along with reduced MDA and LDH levels. Immunofluorescence staining and western blotting revealed that HSYA effectively inhibited the expression of NLRP3, AIM2, Pyrin, Cleaved-Caspase1, GSDMD, ASC, and HMGB1-related proteins. Additionally, ELISA results demonstrated that HSYA suppressed the release of IL18 and IL-1β inflammatory factors in serum. These findings suggest HSYA may alleviate ischemic stroke injury by inhibiting NLRP3, AIM2, and Pyrin inflammasome-mediated pyroptosis, offering a potential therapeutic strategy for cerebral I/R injury.

Indexed as

ChalconeDNA-Binding ProteinsInflammasomesIschemic StrokeNLR Family, Pyrin Domain-Containing 3 ProteinPyroptosisQuinonesAnimalsMaleRatsRats, Sprague-DawleyAIM2 protein, ratChalconeDNA-Binding Proteinshydroxysafflor yellow AInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratQuinonesAIM2Hydroxysafflor yellow AIschemic strokeNLRP3PyrinPyroptosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.